DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tucotuzumab celmoleukin
Tucotuzumab celmoleukin
Tanibirumab (CUI C3490677) Add to Cart
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
WHO Drug Information Vol. 20, No. 3, 2006
Ep 3178848 A1
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
PANI: a Novel Algorithm for Fast Discovery of Putative Target Nodes in Signaling Networks
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
Top View
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
Biotech Drugs: Biological Therapeutic Agents
Epcam Detection
Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS
New Agents – Manifold Consequences: the Management of Lung and Co- Lorectal Cancer Is Changing
Com(2010)0397
The Honorable Shara Aranoff Chairman United States International Trade Commission 500 E Street, S.W. Washington, DC 20436 Dear C
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Combinations of an Anti-HER2 Antibody-Drug Conjugate And
Tumor-Targeted Drug Conjugates As an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
(INN) for Biological and Biotechnological Substances
Timepoint 1 Geting Assembly Complexes (Attacs) for Selectively Activating De¬ Sired Immune Cells in the Tumor Microenvironment
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al
Merck Serono the Largest Division of the Merck Group
Identification of Targets for Rational Pharmacological Therapy in Childhood Craniopharyngioma Jacob M